Patent ID: 8216568

Claim:
A method comprising a step of administering to an individual having deposits of human IgA1 (a) an IgA1 protease selected from the group consisting of Streptococcus pneumoniae IgA1 protease, Streptococcus sanguis IgA1 protease, Clostridium ramosum IgA1 protease, Haemophilus influenzae IgA1 protease, Haemophilus aegyptius IgA1 protease, Neisseria meningitidis type 1 and type 2 IgA1 protease, and Neisseria gonorrhoeae IgA1 protease and (b) another therapy selected from the group consisting of corticosteroids, dietary fish oil supplements, angiotensin converting enzyme inhibitors, and combinations thereof, such that the deposits of IgA1 are reduced.